Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-07264660 in Healthy Participants
NCT05496738Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2022
- Primary completion
- May 2024
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ompekimig in atopic dermatitis (AD) (4 arms), sponsored by Pfizer. Primary endpoints: Number of participants with treatment emergent treatment related adverse events (AE's) up to 1.5 years, Number of participants with treatment emergent treatment-related serious adverse events (SAE's) up to 1.5 years and 5 more. Started Aug 2022; status: completed.
02
Drugs
ompekimig
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05496738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05496738.